Search over 3,000 reports

    Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023

    Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023
    Date: Jul, 2017
    Type: Pharmaceutical Industry Report
    Pages: 242
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0008

    DelveInsight's ‘Peripheral T-Cell Lymphoma (PTCL) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025' report provides provides the comprehensive insights on the competitive landscape and market of Peripheral T-Cell Lymphoma (PTCL).
    The report covers an overview of the Peripheral T-Cell Lymphoma along with the epidemiology and the market scenario in the 7MM - United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.
    The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
    The Report covers detailed historical and forecasted epidemiology of Peripheral T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Anaplastic T Cell Lymphoma, AngioImmunoblastic T Cell Lymphoma, NK/T Cell Lymphoma and others), as well as stages of the disease. According to DelveInsight, the incident cases of Peripheral T-Cell Lymphoma are expected to reach up to 24,630 by the end of 2025 at a CAGR of XX% from 2013 to 2025. High incident cases were observed in the United States as compared to EU5 and Japan.
    The Report covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Peripheral T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Peripheral T-Cell Lymphoma market as compared to EU5 countries and Japan.
    Market is mainly driven by Beleodaq (Spectrum Pharmaceuticals, Inc.), Istodax (Celgene Corporation), Poteligeo (Kyowa Hakko Kirin Co., Ltd. and Folotyn (Spectrum Pharmaceuticals) being approved for the treatment of Peripheral T-Cell Lymphoma.
    The therapeutic market of Peripheral T-Cell Lymphoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 8.3% for the forecasted period i.e., 2013-2025.
    ?
    Key Coverage and Benefits:
    The report will help in developing business strategies by understanding the trends shaping and driving the global Peripheral T-Cell Lymphoma market.
    Overview of the Global pipeline scenario for global Peripheral T-Cell Lymphoma, products and associated companies information
    Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
    Organize sales and marketing efforts by identifying the best opportunities for Peripheral T-Cell Lymphoma in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
    The report provides historical as well as forecasted epidemiology of Peripheral T-Cell Lymphoma in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
    To understand the future market competition in the global Peripheral T-Cell Lymphoma market and Insightful review of the key market drivers and barriers.
    To understand the regulatory scenario in major markets.
    The Report also covers the detailed global historical and forecasted Peripheral T-Cell Lymphoma market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2013-2025.

    Report Introduction
    Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance
    Global Market Size of PTCL in 2016
    Global Market Size of PTCL in 2025
    Overview
    Subtypes of Peripheral T cell lymphoma
    Nodal Peripheral T cell lymphomas
    Extranodal Peripheral T Cell Lymphomas
    Cutaneous- Peripheral T Cell Lymphomas
    Leukemic- Peripheral T Cell Lymphomas
    Pathophysiology
    Staging
    Diagnosis
    Peripheral T-Cell Lymphoma (PTCL) Geography wise Incident Cases
    7MM Incident PTCL Cases in 2016
    7MM Incident PTCL Cases in 2025
    Epidemiology and Patient Population
    Key Points
    United States
    Assumptions and Rationale
    Incident Cases of PTCL in United States
    Stage wise PTCL Cases in United States
    Common Types of PTCL in United States
    Europe
    Assumptions and Rationale
    Germany
    Incident Cases of PTCL in Germany
    Stage wise PTCL Cases in Germany
    Common Types of PTCL Cases in Germany
    Italy
    Incident Cases of PTCL in Italy
    Stage wise PTCL Cases in Italy
    Common Types of PTCL Cases in Italy
    Spain
    Incident Cases of PTCL in Spain
    Stage wise PTCL Cases in Spain
    Common Types of PTCL Cases in Spain
    France
    Incident Cases of PTCL in France
    Stage wise PTCL Cases in France
    Common Types of PTCL Cases in France
    United Kingdom
    Incident Cases of PTCL in United Kingdom
    Stage wise PTCL Cases in United Kingdom
    Common Types of PTCL Cases in United Kingdom
    Japan
    Assumptions and Rationale
    Incident Cases of PTCL in Japan
    Stage wise PTCL Cases in Japan
    Common Types of PTCL Cases in Japan
    Treatment Algorithm
    United States
    Europe
    Unmet Needs
    Marketed Drugs
    Beleodaq (Belinostat): Onxeo S.A.
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Beleodaq
    Product Profile
    Istodax (Romidepsin): Celgene Corporation
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Istodax
    Product Profile
    Folotyn (Pralatrexate): Spectrum Pharmaceuticals
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Folotyn
    Product Profile
    Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Poteligeo
    Product Profile
    Adcetris (Brentuximab vedotin): Seattle Genetics
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Adcetris
    Product Profile
    Rituxan (MabThera): Genentech
    Drug Description
    Mechanism of Action
    Advantages & Disadvantages
    Safety and Efficacy of Rituxan
    Product Profile
    Emerging Therapies
    Phase III
    Brentuximab vedotin: Seattle Genetics
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Masitinib: AB Science SA
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Phase II
    Darinaparsin: Solasia Pharma
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Fenretinide: CerRx, Inc
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Denileukin diftitox: Eisai Co Ltd
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Lenalidomide: Celgene Corporation
    Advantages & Disadvantages
    Product Profile
    Clinical Development
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Market Size
    Global PTCL Market Analysis
    Overview of Global PTCL Market (2013-2025)
    Total 7MM PTCL Market Analysis
    Overview of Total PTCL Market (2013-2025)
    PTCL Region wise Market Analysis
    Region wise Market Size (2016)
    Region wise Market Size (2025)
    7MM PTCL: Country-Wise Market Analysis
    Overview on Total PTCL Market (2016)
    Overview on Total PTCL Market (2025)
    Global PTCL: Market Analysis
    United States Market Size
    Europe Market Size
    Germany Market Size
    France Market Size
    United Kingdom Market Size
    Spain Market Size
    Italy Market Size
    Japan Market Size
    Market Drivers
    Market Barriers
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight

    Table 1: Incident Cases of PTCL in United States (2013-2025)
    Table 2: Stage wise number of cases in United States (2016)
    Table 3: Common Types of cases in United States (2016)
    Table 4: Incident Cases of PTCL in Germany (2013-2025)
    Table 5: Stage wise number of cases in Germany (2016)
    Table 6: Common Types of cases in Germany (2016)
    Table 7: Incident Cases of PTCL in Italy (2013-2025)
    Table 8: Stage wise number of cases in Italy (2016)
    Table 9: Common Types of cases in Italy (2016)
    Table 10: Incident Cases of PTCL in Spain (2013-2025)
    Table 11: Stage wise number of cases in Spain (2016)
    Table 12: Common Types of cases in Spain (2016)
    Table 13: Incident Cases of PTCL in France (2013-2025)
    Table 14: Stage wise number of cases in France (2016)
    Table 15: Common Types of cases in France (2016)
    Table 16: Incident Cases of PTCL in United Kingdom (2013-2025)
    Table 17: Stage wise number of cases in United Kingdom (2016)
    Table 18: Common Types of cases in United Kingdom (2016)
    Table 19: Incident Cases of PTCL in Japan (2013-2025)
    Table 20: Stage wise number of cases in Japan (2016)
    Table 21: Common Types of cases in Japan (2016)
    Table 22: List of Marketed Drugs for Peripheral T Cell Lymphoma
    Table 23: List of Emerging therapies for Peripheral T- Cell Lymphoma
    Table 24: Brentuximab Vedotin, Clinical Trials by Zone, 2017
    Table 25: Clinical Trials by Trial status, 2017
    Table 26: Masitinib, Clinical Trials by Zone, 2017
    Table 27: Clinical Trials by Trial status, 2017
    Table 28: Darinaparsin, Clinical Trials by Zone, 2017
    Table 29: Clinical Trials by Trial status, 2017
    Table 30:Fenretinide, Clinical Trials by Zone, 2017
    Table 31: Clinical Trials by Trial status, 2017
    Table 32: Denileukin diftitox, Clinical Trials by Zone, 2017
    Table 33: Clinical Trials by Trial status, 2017
    Table 34: Lenalidomide, Clinical Trials by Zone, 2017
    Table 35: Clinical Trials by Trial status, 2017
    Table 36: Global Market Size of PTCL in USD Million, (2013-2025)
    Table 37: Market Size of PTCL-7MM in USD Million (2013-2025)
    Table 38: Total PTCL , Market Revenue (2016) as per the 7MM
    Table 39: Total PTCL , Market Revenue (2025) as per the 7MM
    Table 40: Market Size of PTCL-United States in USD Million (2013-2025)
    Table 41: Market Size of PTCL-Germany in USD Million (2013-2025)
    Table 42: Market Size of PTCL-France in USD Million (2013-2025)
    Table 43: Market Size of PTCL-United Kingdom in USD Million (2013-2025)
    Table 44: Market Size of PTCL-Spain in USD Million (2013-2025)
    Table 45: Market Size of PTCL-Italy in USD Million (2013-2025)
    Table 46: Market Size of PTCL-Japan in USD Million (2013-2025)

    Figure 1: Classification of Peripheral T- Cell Lymphoma
    Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
    Figure 3: Incident Cases of PTCL in United States (2013-2025)
    Figure 4: Stage wise PTCL cases in United States (2013-2025)
    Figure 5: Common types of PTCL in United States (2013-2025)
    Figure 6: Incident Cases of PTCL in Germany (2013-2025)
    Figure 7: Stage wise PTCL cases in Germany (2013-2025)
    Figure 8: Common types of PTCL in Germany (2013-2025)
    Figure 9: Incident Cases of PTCL in Italy (2013-2025)
    Figure 10: Stage wise PTCL cases in Italy (2013-2025)
    Figure 11: Common types of PTCL in Italy (2013-2025)
    Figure 12: Incident Cases of PTCL in Spain (2013-2025)
    Figure 13: Stage wise PTCL cases in Spain (2013-2025)
    Figure 14: Common types of PTCL in Spain (2013-2025)
    Figure 15: Incident Cases of PTCL in France (2013-2025)
    Figure 16: Stage wise PTCL cases in France (2013-2025)
    Figure 17: Common types of PTCL in France (2013-2025)
    Figure 18: Incident Cases of PTCL in United Kingdom (2013-2025)
    Figure 19: Stage wise PTCL in United Kingdom (2013-2025)
    Figure 20: Common types of PTCL in United Kingdom (2013-2025)
    Figure 21: Incident Cases of PTCL in Japan (2013-2025)
    Figure 22: Stage wise PTCL cases in Japan (2013-2025)
    Figure 23: Common Types of PTCL in Japan (2013-2025)
    Figure 24: First Line of therapy for PTCL -NOS
    Figure 25: Second Line of therapy for PTCL - NOS with Stem cell transplant
    Figure 26: First Line of therapy for ALCL, ALK+
    Figure 27: Second Line of therapy for ALCL- ALK+ with Stem cell transplant
    Figure 28: First Line of therapy for ALCL, ALK-
    Figure 29: Second Line of therapy for ALCL- ALK- with Stem cell transplant
    Figure 30: First Line of therapy for AICL
    Figure 31: Second Line of therapy for AICL with Stem cell transplant
    Figure 32: First Line of therapy for Enteropathy associated TCL
    Figure 33: Second Line of therapy for enetropathy associated T cell lymphoma with stem cell transplantation
    Figure 34: Treatment for Nodal and Extranodal Peripheral T cell Lymphomas
    Figure 35: Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T cell Lymphomas
    Figure 36: Brentuximab vedotin, Clinical Trials by Zone (%), 2017
    Figure 37: Brentuximab Vedotin, Clinical Trials by Trial status (%), 2017
    Figure 38: Masitinib, Clinical Trials by Zone (%), 2017
    Figure 39: Masatinib, Clinical Trials by Trial status (%), 2017
    Figure 40: Darinaparsin, Clinical Trials by Zone (%), 2017
    Figure 41: Darinaparsin, Clinical Trials by Trial status (%), 2017
    Figure 42: Fenretinide, Clinical Trials by Zone (%), 2017
    Figure 43: Fenretinide, Clinical Trials by Trial status (%), 2017
    Figure 44: Denileukin diftitox, Clinical Trials by Zone (%), 2017
    Figure 45: Denileukin diftitox, Clinical Trials by Trial status (%), 2017
    Figure 46: Lenalidomide, Clinical Trials by Zone (%), 2017
    Figure 47: Lenalidomide, Clinical Trials by Trial status (%), 2017
    Figure 48: Global Market Size of PTCL in USD Millions (2013-2025)
    Figure 49: Market Size of PTCL- 7MM in USD Millions (2013-2025)
    Figure 50: Market Size of PTCL Country-wise in USD Millions (2016)
    Figure 51: Market Size of PTCL Country-wise in USD Millions (2025)
    Figure 52: Market Size of PTCL in United States in USD Millions (2013-2025)
    Figure 53: Market Size of PTCL in Germany in USD Millions (2013-2025)
    Figure 54: Market Size of PTCL in France in USD Millions (2013-2025)
    Figure 55: Market Size of PTCL in United Kingdom in USD Millions (2013-2025)
    Figure 56: Market Size of PTCL in Spain in USD Millions (2013-2025)
    Figure 57: Market Size of PTCL in Italy in USD Millions (2013-2025)
    Figure 58: Market Size of PTCL in Japan in USD Millions (2013-2025)

    Sirion Therapeutics

    Valeant Pharmaceuticals International Inc.

    Allergan plc

    Alcon Pharmaceuticals

    Abbvie

    Aldeyra Therapeutics

    pSivida Corp.

    Santen Pharmaceutical Co. Ltd.

    Sanofi Aventis

    • Single User License
      $6,950.00
    • Site License
      $13,900.00
    • Global License
      $20,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap